A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

NCT02237157 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Gemcitabine, local delivery

Sponsor

RenovoRx